Biostax Corp (f/k/a Immune Therapeutics) name change to BTAX approved; pivots to substance abuse & HIV

Biostax Corp.

Name change from Immune Therapeutics, Inc. to Biostax Corp effective Oct 5, 2023; FINRA approved Oct 20.
New ticker symbol BTAX on OTC Pink Markets; old stock certificates remain valid.
Strategic pivot to commercialize substance abuse solutions internationally and advance HIV treatment.
Combining naltrexone technology with Immgenuity's IMTV014 vaccine platform for HIV/NeuroAIDS.
CEO Noreen Griffin signals future commercial partnership updates and website launch in coming quarters.

item 5.03 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Biostax Corp.: Changed corporate name from Immune Therapeutics, Inc. to Biostax Corp (effective 2023-10-05).

Change: charter amendment
Effective: 2023-10-05

Exact text from the filing

On October 5, 2023, Immune Therapeutics, Inc. d/b/a Biostax Corp (the “Company”) filed a Articles of Amendment to the Articles of Incorporation (“Amendment”) with the Secretary of State of the State of Florda to change its corporate name from Immune Therapeutics, Inc. to Biostax Corp., effective October 5, 2023.

View on SEC.gov

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Biostax Corp.: Amended bylaws to reflect the corporate name change to Biostax Corp (effective 2023-10-05).

Change: bylaw amendment
Effective: 2023-10-05

Exact text from the filing

In connection with the Company’s name change, the board of directors amended the Company’s bylaws to reflect the corporate name Biostax Corp., also effective on October 5, 2023.

View on SEC.gov

Browse all governance changes →

Source: SEC EDGAR

accession 0001493152-23-038052

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.